Continuous subcutaneous administration of teriparatide as a therapeutic option in chronic hypoparathyroidism: retrospective study in three tertiary care centers of the epi-hypo study
Authors' conclusion
CSAT may be an option for patients with uncontrolled cHP. Further studies need to investigate bone consequences and better characterize the improvement of QoL among these patients.
Study context
- Population
- Patients with chronic hypoparathyroidism uncontrolled despite oral treatment, who received continuous subcutaneous administration of teriparatide (CSAT), 3 tertiary care centers of the Epi-Hypo study; 85% women, 75% post-surgery chronic hypoparathyroidism (cHP)
- Participants
- 20 patients
- Exposure
- CSAT vs previous treatment
- Outcome
- Evolution of biological parameters with CSAT vs previous treatment
Methodological detailsmulticentre, 3 tertiary care centers
- Multicentre
- 3 tertiary care centers
Main finding
As reported in the abstract
Total calcium concentration
Total calcium significantly higher with CSAT than with injections of teriparatide (IST)
73% patients
Observational data: associations, not effects.
Further findings
Quality of life (QoL) (Hypoparathyroid Patient Questionnaire (HPQ28))
- HPQ28 improved in patients assessed
- 3 of 5
Osteocalcin
- Osteocalcin increased significantly with IST
- P = 0.003
- No difference observed after initiating CSAT
Original publication
Continuous subcutaneous administration of teriparatide as a therapeutic option in chronic hypoparathyroidism: retrospective study in three tertiary care centers of the epi-hypo study. Eur J Endocrinol. Published 24 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →